Key Points
- EVP Joseph Laplume sold 400 shares of Charles River at an average price of $163.72 on Aug. 22 for $65,488, reducing his stake to 23,716 shares (a 1.66% ownership decrease), according to an SEC filing.
- Latest quarter beat estimates: Charles River reported $2.43 EPS (vs. $2.32 expected) and $1.0B revenue (vs. $990.4M expected), though the company still showed a negative net margin and slight year-over-year revenue decline.
- Analyst and market view: The stock has a $10.74B market cap and an average analyst rating of "Moderate Buy" with an average target of $209.46, while institutional investors own roughly 98.9% of the shares.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Joseph Laplume sold 400 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $163.72, for a total transaction of $65,488.00. Following the transaction, the executive vice president directly owned 23,716 shares of the company's stock, valued at $3,882,783.52. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Charles River Laboratories International Stock Down 0.7%
CRL stock opened at $218.13 on Wednesday. The company has a market capitalization of $10.74 billion, a P/E ratio of -139.83, a price-to-earnings-growth ratio of 6.57 and a beta of 1.61. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The firm's fifty day simple moving average is $193.71 and its 200-day simple moving average is $175.13. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. During the same period in the previous year, the firm posted $2.59 earnings per share. The firm's quarterly revenue was down .5% on a year-over-year basis. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Tema Etfs LLC purchased a new stake in Charles River Laboratories International in the 4th quarter worth $26,000. Cromwell Holdings LLC lifted its holdings in Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company's stock valued at $27,000 after purchasing an additional 152 shares in the last quarter. Rothschild Investment LLC grew its position in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock valued at $29,000 after purchasing an additional 84 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Charles River Laboratories International during the second quarter worth about $29,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of Charles River Laboratories International during the third quarter worth about $31,000. Hedge funds and other institutional investors own 98.91% of the company's stock.
Wall Street Analysts Forecast Growth
CRL has been the topic of several analyst reports. Evercore ISI raised their target price on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, January 13th. Weiss Ratings restated a "sell (d)" rating on shares of Charles River Laboratories International in a research report on Wednesday, October 8th. TD Cowen cut their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a "buy" rating for the company in a report on Monday, November 10th. Argus set a $200.00 target price on shares of Charles River Laboratories International in a research note on Monday, November 17th. Finally, Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Moderate Buy" and an average target price of $209.46.
Get Our Latest Analysis on CRL
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
